Rinaton M 2.5/1000 mg
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Pavis Pharmaceutical Co., Ltd.
MFDS item code 201901622 · Approved 2019.03.18
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes. It may be administered as monotherapy initially or when sufficient control is not achieved with metformin alone. Additionally, it may be used in conjunction with metformin and sulfonylureas when blood glucose control is inadequate. If there is insufficient blood glucose control with a regimen that includes insulin and metformin, it can be combined with insulin, and if blood glucose management is difficult with empagliflozin and metformin, it can also be co-administered with empagliflozin. This medication effectively improves blood glucose control in various combination therapy settings.
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently treated with metformin: For patients with no prior experience of antidiabetic drug therapy whose blood glucose is not adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine should comprise linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from concomitant therapy with linagliptin and metformin: Patients switching from concomitant therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with concomitant therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to comprise linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered concomitantly with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for use, 3. Administration with caution to the following patients). 5. Patients whose blood glucose is not adequately controlled with concomitant therapy with insulin and metformin: The initial dose of this medicine should be considered to comprise linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for use, 3. Administration with caution to the following patients). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may lead to changes in blood glucose control; caution and appropriate monitoring are required. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m², this medicine should be discontinued immediately. Patients with hepatic impairment Due to its metformin component, this medicine should not be administered to patients with hepatic impairment (see Precautions for use, 2. Do not administer to the following patients).
This medication can cause a rare but serious side effect called lactic acidosis, so it should not be used especially in patients with impaired kidney function or those with heart and liver diseases. Patients allergic to any ingredients in this medication, or those with type 1 diabetes or diabetic ketoacidosis should not take it. It is advisable not to use this medication in cases of acute infections, dehydration, severe trauma, shock, or any conditions that may lead to rapid deterioration of kidney function. Women who are pregnant or breastfeeding should not take this medication, and it is also advisable to avoid its use if planning a pregnancy. The risk of hypoglycemia exists, so caution should be exercised for symptoms of low blood sugar when used with other hypoglycemic agents such as sulfonylureas or insulin, and dosage adjustments may be necessary. Elderly patients or those taking medications that may affect kidney function should undergo regular kidney function tests. During treatment with this medication, symptoms of acute pancreatitis or skin disorders such as bullous pemphigoid may occur, and should abdominal pain or skin rash arise, immediate consultation with a physician is required. Since there may be a decrease in vitamin B12 levels, regular blood testing for vitamin B12 status is advisable with prolonged use. This medication can be taken irrespective of meal timing; however, it is recommended to be taken during or after meals to minimize gastrointestinal discomfort. Interactions between this medication and others may occur, so it is essential to inform the physician or pharmacist of any other medications being taken. Due to the risk of lactic acidosis, this medication should be discontinued immediately and medical consultation sought in case of severe vomiting, diarrhea, or other signs of dehydration. This medication should be temporarily discontinued before surgery or radiological testing and resumed only after kidney function has recovered. Children and those under 10 years old should not use this medicine due to insufficient data on its safety and efficacy in this age group. Although no studies have been conducted regarding its effects on driving or machinery operation, caution is advised due to the possibility of hypoglycemic symptoms. In cases of overdose, gastrointestinal symptoms or lactic acidosis may occur, and appropriate medical treatment should be sought immediately. This medication should be stored in a sealed container, away from moisture and direct sunlight, and should not be transferred to another container.
Lactic acidosis, hypoglycemia, dysgeusia, cough, anorexia, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcer formation, abnormal liver function tests, hepatitis, pruritus, erythema, rash, vesicular pemphigoid, increased lipase, increased amylase, nasopharyngitis, hypersensitivity, angioedema, urticaria, decreased and deficient vitamin B12, cheilitis, stomatitis, constipation, epigastric pain, enterocolitis, bowel obstruction, gastritis, shingles, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, cerebral infarction, speech disorder, Alzheimer's dementia, chest pain, fever, facial edema, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot, skin lesions, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscal injury, pneumoconiosis, congestive heart failure, angina, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, kidney transplant failure, hyperglycemia, vertigo, drowsiness, itching, insomnia, depression, hypertension, benign prostatic hyperplasia, angina, acute myocardial infarction, unstable angina, stomatitis, mediastinitis, vitreous hemorrhage, ligament sprain, flank pain, myelodysplastic syndromes, vocal cord polyp, dyspepsia, anal bleeding, dental caries, enteritis, gastritis, gingivitis, influenza, altered mental status, nocturia, dermatitis, hypotension, flushing, hearing loss, erectile dysfunction, goiter, altered mental status, decreased hemoglobin, increased potassium in blood, increased creatinine in blood, increased creatine phosphokinase in blood, increased ALT, increased AST, increased triglycerides in blood, increased urine albumin/creatinine ratio, positive urine leukocytes, increased blood glucose, increased creatinine in blood, increased creatinine in blood
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, and must be stored in a sealed container. It is also important to keep it at room temperature between 1 and 30 degrees Celsius to maintain its effectiveness.
Bright pink, oval, film-coated tablet with both sides convex
60 tablets (10 tablets / PTP) x 6
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Pavis Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Anguk Pharm Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.